EMBRYONIC DEVELOPMENT & STEM CELL COMPENDIUM
Content
All Cell Therapies > Cell Therapy Card
Sign in for full access

Hearticellgram®-AMI, mesenchymal stem cells for acute myocardial infarction

Hearticellgram®-AMI are bone marrow-derived mesenchymal stem cells (MSCs) used to treat acute myocardial infarction through intracorononary injection. This study assessed the safety and efficacy of intracoronary autologous transplantation of bone marrow-derived human MSCs in patients with acute myocardial infarction. There were no adverse reactions or major cardiac events. There was an improvement in left ventricular ejection fraction, already evident 6hrs after treatment, in acute myocardial function patients who underwent percutaneous transluminal coronary angiography within 72 hrs of chest pain onset.

This was  the first licensed stem cell treatment to use bone marrow–derived stem cells to treat diseases outside of the blood and immune systems. The approval was by the Korean FDA.
See additional Cell Therapies for: Heart
Hearticellgram®-AMI, mesenchymal stem cells for acute myocardial infarction